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ABSTRACT (75 WORDS) 
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium 
(CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the 
published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-
guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical 
genotype results are available. In addition, this updated guideline incorporates recommendations 
for adult and pediatric patients that are specific to continental ancestry.   
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INTRODUCTION 
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large inter-patient 
variability in the dose required to achieve target anticoagulation.  Common genetic variants in 
CYP2C9, VKORC1, CYP4F2 and the CYP2C cluster (e.g., rs12777823), plus known non-genetic 
factors, account for ~50% of warfarin dose variability. This document is an update to the 2011 
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and 
VKORC1 genotypes and warfarin dosing and aims to assist in the interpretation and use of 
CYP2C9, VKORC1, CYP4F2, and rs12777823 genotypes to estimate therapeutic warfarin dose 
among patients with a target international normalized ratio (INR) of 2-3, should clinical 
genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation 
Consortium (CPIC) of the National Institute of Health’s Pharmacogenomics Research Network 
develops peer-reviewed gene/drug guidelines that are published and updated periodically on 
https://cpicpgx.org/genes-drugs/ and http://www.pharmgkb.org based upon new developments in 
the field (1). These guidelines were written with a global audience in mind, although the majority 
of the data that underpin these guidelines arise from people of European ancestry, East Asia and 
African Americans. 
 
FOCUSED LITERATURE REVIEW 
The Supplement includes a systematic literature review on CYP2C9, VKORC1, CYP4F2 and 
other relevant genes/genotypes that have been associated with warfarin dosing.  This systematic 
review forms the basis for the recommendations contained in this guideline.  Although some of 
these genes have also been associated with dose of other coumarin anticoagulants, the 
recommendations below are specific to warfarin.   
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DRUG: WARFARIN 
Warfarin (Coumadin® and others) is the most commonly used oral anticoagulant worldwide, 
with annual prescriptions in the Western world typically equaling 0.5 to 1.5% of the population 
(2).  It is prescribed for treatment and prevention of thromboembolic disorders (3). Although 
highly efficacious, warfarin dosing is notoriously challenging due to its narrow therapeutic index 
and wide inter-individual variability in dose requirements even among patients with the same 
target INR (4). Complications from inappropriate warfarin dosing are among the most frequently 
reported adverse events to the U.S. Food and Drug Administration (FDA) and one of the most 
common reasons for emergency room visits (5). 
  
Warfarin is usually dosed empirically: an initial dose is prescribed, typically followed by at least 
weekly measurement of the INR and subsequent dose adjustment.  The initial dose is often based 
on population averages (e.g., 4-5 mg/day), but in some settings, it is common to use loading 
doses during the first few days of anticoagulation.  Irrespective of the method used to initiate 
warfarin, stable doses to achieve an INR of 2-3 range from 1 to 20 mg/day.  The iterative process 
to define the appropriate dose can take weeks to months and during this period, patients are at 
increased risk of over- or under-anticoagulation, and thus risk of bleeding or thromboembolism.   
 
Warfarin pharmacology and pharmacokinetics.  Figure 1 highlights key elements of warfarin 
pharmacology and pharmacokinetics.  Warfarin inhibits vitamin K epoxide reductase complex 
(6) and is administered as a racemic mixture, with S-warfarin being more potent than R-warfarin 
(3).  
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GENES: CYP2C9, VKORC1 AND CYP4F2 
There is substantial candidate gene literature evaluating associations with warfarin dose 
requirements, as well as several reported genome-wide association studies (Supplemental 
Tables S1-S7).  The genes with the strongest literature support, and for which we make 
recommendations for use in warfarin dosing, are CYP2C9, VKORC1 and CYP4F2.  Additionally, 
genome-wide association studies have identified an independently significant single nucleotide 
polymorphism (SNP) in the CYP2C cluster (7), which has also been incorporated into this 
updated recommendation.    
 
CYP2C9 and warfarin 
CYP2C9 is a hepatic drug-metabolizing enzyme in the cytochrome P450 (CYP450) superfamily 
(8), and is the primary metabolizing enzyme of S-warfarin (Figure 1). CYP2C9 has over 60 
known variant alleles (http://www.cypalleles.ki.se/cyp2c9.htm; CYP2C9 allele definition table 
(9)).  Individuals homozygous for the reference CYP2C9 allele (CYP2C9*1) have the “normal 
metabolizer” phenotype.  Each named CYP2C9 star (*) allele is defined by one or more specific 
SNPs and to date, and 18 alleles have been associated with decreased enzyme activity (CYP2C9 
allele definition table-(9)).  The two most common decreased function alleles among 
individuals of European ancestry are CYP2C9*2 (c.430C>T; p.Arg144Cys; rs1799853) and 
CYP2C9*3 (c.1075A>C; p.Ile359Leu; rs1057910) (8).  CYP2C9 allele frequencies differ 
between racial/ethnic groups (8, 10). 
 
In vitro and in vivo studies suggest CYP2C9*2 and *3 impair metabolism of S-warfarin by ~30-
40% and ~80-90%, respectively (8).  Compared to patients homozygous for CYP2C9*1, 
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individuals who inherit one or two copies of CYP2C9*2 or *3 are at greater risk of bleeding 
during warfarin therapy (11, 12), require lower doses to achieve similar levels of anticoagulation, 
and require more time to achieve a stable INR (11) (Supplemental Table S1).  Additional 
CYP2C9 alleles (CYP2C9*5, *6, *8, and *11) are associated with decreased function of the 
CYP2C9 enzyme and contribute to dose variability.  These alleles are found with the highest 
frequency among those of African ancestry, and collectively are more common than CYP2C9*2 
and *3 in that population (CYP2C9 frequency table; (9)). 
 
VKORC1 and warfarin 
VKORC1 encodes the vitamin K epoxide reductase protein, the target enzyme of warfarin (6). 
VKORC1 catalyzes the conversion of vitamin K-epoxide to vitamin K, which is the rate-limiting 
step in vitamin K recycling (13).  
 
A common variant upstream of VKORC1 (c.-1639G>A, rs9923231) is significantly associated 
with warfarin sensitivity and patients with one or two -1639A require progressively lower 
warfarin doses than -1639G/G homozygotes (10, 14-18). The -1639G>A polymorphism is 
present on a haplotype that affects VKORC1 protein expression. (18).  
 
Other common VKORC1 SNPs or haplotypes do not further improve warfarin dose prediction 
(10, 16).  The c.-1639G>A allele frequency varies among different ancestral populations 
(VKORC1 frequency table; (19)), and largely explains the differences in average dose 
requirements between whites, blacks and Asians (10, 17).  Several rare non-synonymous 
VKORC1 variants confer warfarin resistance (high dose requirements) and are detailed in 
Supplemental Table S2 (20).   
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CYP4F2 and warfarin 
CYP4F2 is a primary liver vitamin K oxidase that catalyzes the metabolism of vitamin K to 
hydroxy-vitamin K1 and removes vitamin K from the vitamin K cycle (21) (Figure 1). It acts as 
an important counterpart to VKORC1 in limiting excessive accumulation of vitamin K. The non-
synonymous variant CYP4F2*3 (c.1297G>A; p.Val433Met; rs2108622) was first shown to 
affect enzyme activity and associated with warfarin dose in three independent white cohorts (22-
24).  Furthermore, including this CYP4F2 variant in warfarin dosing models that included 
CYP2C9, VKORC1 and clinical factors improved the accuracy of dose prediction (25). This 
correlation has been confirmed in subsequent studies with those of European and Asian ancestry, 
though not those of African ancestry (26, 27).  Two large meta-analyses (one in Han Chinese that 
pulled in substantial Chinese literature) provide the best estimates for the influence data of 
CYP4F2*3 on warfarin dose requirements (26, 27). They suggest statistically significant but 
modest impacts of 8-11% higher warfarin doses in A allele carriers (Supplemental Table S3).  
 
CYP2C rs12777823 and warfarin 
rs12777823 is a SNP in the CYP2C cluster near the CYP2C18 gene on chromosome 10 and is 
associated with a clinically relevant effect on warfarin dose through significant alterations in 
warfarin clearance, independent of CYP2C9*2 and *3 (7). This association was first identified 
through a genome-wide association study in African Americans (p=1.51x10-8) and confirmed in 
a replication cohort (p=5.04×10−5); meta-analysis of the two cohorts together produced a p value 
of 4.5 ×10−12. This study concluded that African Americans who are heterozygous or 
homozygous for the rs12777823 A allele require a dose reduction of ~ 7 or 9 mg/week, 
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respectively (7). Regression analysis showed that addition of this SNP improves the dosing 
algorithm published by the International Warfarin Pharmacogenetics Consortium (IWPC) by 
21%. Further studies have demonstrated the importance of this SNP in African Americans (28). 
Although this variant is common in other ethnic populations, an association with warfarin dose 
has only been detected among African Americans suggesting it is not the underlying cause but 
likely inherited with other variant(s) on a haplotype that influences warfarin dose in this 
population.  Of note, an association was not observed in a cohort of Egyptians, thus it is not 
possible to make broad statements about this allele in people of continental African ancestry. 
Most African Americans are of West African ancestry; it is unknown whether similar 
associations are present in individuals from other parts of Africa. 
 
Genetic Test Interpretation  
CYP2C9. Clinical laboratories typically report CYP2C9 genotype results using the star (*) allele 
nomenclature system and an interpretation that includes a predicted metabolizer phenotype.  
Most FDA-approved CYP2C9 tests include only *2 and *3, which is not as informative for 
African ancestry populations; however, some clinical laboratories may offer expanded CYP2C9 
panels validated as laboratory developed tests (LDTs) (for allele frequencies see: CYP2C9 
frequency table (9)).  
 
VKORC1. Clinical laboratories typically report VKORC1 genotype results by c.-1639G>A (or 
the linked 1173C>T; rs9934438) genotype (e.g., G/A) and an interpretation on warfarin 
sensitivity.  Most commercial genotyping platforms do not detect rare VKORC1 variants that 
have been associated with warfarin resistance (VKORC1 frequency table (19)).  
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CYP4F2. Although not as commonly tested for as CYP2C9 and VKORC1, some clinical 
laboratories may also test for CYP4F2 using a targeted genotyping laboratory developed test to 
detect CYP4F2*3 (c.1297G>A, p.Val433Met; rs2108622) variant. Results are typically reported 
by nucleotide (e.g., G/A), amino acid (e.g., Val/Met) or star (*) allele (*1/*3) genotype and an 
interpretation related to warfarin dosing.   
 
CYP2C rs12777823. Given the recent identification of the association between rs12777823 
(g.96405502G>A) and warfarin dosing among African Americans, most clinical laboratories do 
not currently include this non-coding variant in their warfarin pharmacogenetic genotyping 
panels.  However, the increasing accessibility of clinical research genomics programs that return 
actionable results and the notable effect of this variant among African Americans suggests that 
some patients may have genotype results for this variant in the future.  Results would likely be 
reported by genotype (e.g., G/A) and an interpretation related to warfarin dosing. 
 
Genetic test options 
Commercially available genetic testing options change over time. Additional information about 
pharmacogenetic testing can be found at the Genetic Testing Registry 
(http://www.ncbi.nlm.nih.gov/gtr/).  
 
Incidental findings 
No diseases have been linked to common CYP2C9 variants independent of drug metabolism and 
response.  Similarly, no diseases have been consistently linked to common VKORC1 and 
CYP4F2 variants that are interrogated in warfarin response tests. However, homozygosity for 
rare coding mutations in VKORC1 are a known cause of combined deficiency of vitamin K-
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dependent clotting factors-2 (VKCFD2), which is a rare and potentially fatal bleeding disorder 
that can be reversed by oral administration of vitamin K (29). 
 
Linking genetic variability to variability in drug-related phenotypes   
Common variants in CYP2C9, VKORC1, and CYP4F2 account for up to 18%, 30%, and 11% 
respectively, of the variance in stable warfarin dose among patients of European ancestry (10, 
16, 17, 30, 31), but because of differing allele frequencies across populations, these variants 
explain less of the dose variability in patients of other ancestries. In particular, CYP2C9*2 is 
virtually absent in Asians, and additional CYP2C9 alleles (e.g. *5, *6, *8, and *11 alleles) occur 
almost exclusively in persons of African ancestry and contribute to dose variability in this 
population. Other genes of potential importance are discussed in the Supplemental Material.   
 
Published in 2013, the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) and 
Clarification of Optimal Anticoagulation through Genetics (COAG) trials examined the efficacy 
of genotype-guided warfarin dosing in randomized controlled trials (32, 33). In a homogenous 
European population, the EU-PACT trial showed shorter time to stable dose, improved percent 
time in therapeutic range, and reduced number of episodes with an INR>4 using a 
pharmacogenetic dosing algorithm compared to standard dosing (33). The COAG trial was 
conducted in an ethnically diverse cohort with 27% of participants of African ancestry (32). 
Overall, COAG did not show a difference in time to stable dose, percent time in therapeutic 
range, reduction in number of episodes with INR >4 or <2, or bleeding risk with a 
pharmacogenetic dosing algorithm compared to a clinical algorithm. In non-blacks, the 
pharmacogenetic dosing algorithm arm had more patients whose stable dose was within 1 mg per 
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day of the algorithm-predicted dose (57 vs 39%, respectively).  In contrast, the pharmacogenetic 
dosing algorithm was less accurate at predicting within 1 mg/day of the stable dose than the 
clinical algorithm in blacks (38 vs 48% respectively) (32). Blacks were more likely to have an 
INR above range with pharmacogenetic dosing, which could be due to the genotyping panel in 
the COAG trial being limited to CYP2C9*2, *3 and VKORC1 c.-1639G>A.  Other variants that 
influence warfarin dose and are more common in blacks (i.e., CYP2C9*5, *6, *8, and *11 and 
rs12777823) were not genotyped in the COAG trial and their absence likely led to significant 
overdosing in patients with these alleles (10, 34).  Consequently, this updated CPIC guideline 
recommends against pharmacogenetic dosing of warfarin in blacks when only CYP2C9*2 and *3 
genotype results are available.  
 
The Genetics-InFormatics Trial (GIFT) is an on-going randomized controlled trial examining the 
effectiveness and safety of genotype-guided dosing in orthopedic patients with composite 
endpoints for symptomatic and asymptomatic venous thromboembolism, major hemorrhage, 
INR ≥ 4, and death (35). GIFT includes genotyping for CYP2C9*2 and *3, CYP4F2*3, and 
VKORC1-1639, but does not include the African-specific CYP2C9 alleles or rs12777823. At the 
time of this publication, results from the GIFT trial were not available. 
 
Therapeutic Recommendations: Adults 
Recommendations for warfarin maintenance (chronic) dosage based on genetic information. 
We use the three-tiered rating system described previously (and in Supplemental Material) (1) 
in which ratings of strong, moderate, and optional are applied based on the evidence reviewed.  
The recommendations for dosing based on genotype contained herein include recommendations 
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and are derived from numerous observational and prospective studies, and randomized trials that 
suggest the ability to more accurately identify stable therapeutic warfarin dose requirements 
through use of both genetic and clinical information.  Data from prospective studies and 
randomized controlled trials are equivocal on whether the improvement in dosing prediction by 
pharmacogenetics dosing leads to improved clinical outcomes.  The majority of the literature 
underpinning these guidelines arises from individuals of European ancestry, African Americans, 
and East Asians. However, the more limited literature in other populations generally suggests the 
guidelines are appropriate in them also.   
 
Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic 
factors to predict warfarin dose (16, 17, 36, 37).  Two algorithms perform well in estimating 
stable warfarin dose (16, 17) and were created using more than 5000 subjects, though as noted 
above, more recent data suggest they do not perform acceptably in African Americans when used 
without modification for CYP2C9 alleles frequently found in the African population (32).  The 
Gage and IWPC algorithms or minor adjustments to them have also been the algorithms used in 
both randomized controlled trials and most of the prospective dosing studies.  Dosing algorithms 
using genetic information outperform non-genetic clinical algorithms and fixed-dose approaches 
in dose prediction, except in African Americans when the algorithm only includes CYP2C9*2 
and *3 (16, 17, 32). Genetics-based algorithms also better predict warfarin dose than the FDA-
approved warfarin label table (38).   
 
Pharmacogenetic algorithm-based warfarin dosing.  This guideline recommends that 
pharmacogenetic warfarin dosing be accomplished through the use of one of the 
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pharmacogenetic dosing algorithms described above, as summarized in Figure 2.  These 
algorithms, as originally published, are available in the Supplement and the dosing algorithm 
published by IWPC is also online at 
http://www.pharmgkb.org/do/serve?objId=PA162372936&objCls=Dataset#tabview=tab2.  The 
two algorithms provide very similar dose recommendations.  The clinical and genetic 
information used in one or both algorithms is shown in box 1.  These algorithms compute the 
anticipated stable daily warfarin dose to one decimal and the clinician must then prescribe a 
regimen (e.g., an estimate of 4.3 mg/day might be given as 4 mg daily except 5 mg two days per 
week).  An additional “dose revision” algorithm, that can be used on days 4-5 of therapy for dose 
refinement and uses genetic information, was tested in COAG and EU-PACT and can also be 
used (36) (Supplemental Table S5). 
 
It is important to note that these algorithms do not include CYP4F2, CYP2C9*5, *6, *8, or *11 
or rs12777823, and incorporation of these should be added when results are available, as 
described in Figure 2.  Thewarfarindosing.org website contains both algorithms, the Gage 
algorithm (16) as the primary algorithm and the IWPC algorithm (17) as the secondary algorithm 
and can adjust for CYP4F2, CYP2C9*5 and *6.  If utilizing warfarindosing.org, the user should 
be clear on whether the algorithm is or is not incorporating genotypes beyond CYP2C9 *2 and *3 
and VKORC1, which are the only three genotypes in the original version of both algorithms.  
 
Pharmacogenetics-informed loading (or initiation) dose calculations. 
The use of a different initial warfarin dose (or “loading dose”) is somewhat controversial and 
plays different roles in different regions of the world, based on experience and local standards. 
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Recent data from a diverse U.S. based cohort suggest that failure to provide a loading dose in 
patients with zero or one variant alleles in VKORC1 or CYP2C9 may delay time to therapeutic 
INR and reduce time in therapeutic range in the initial month of therapy (39) .  A genetically-
guided loading dose approach was developed by Avery et al. (37) and a slightly modified version 
was successfully implemented in the EU-PACT trial (33).  In COAG CYP2C9 variant alleles 
were not considered for the initial dose, providing a small loading dose on day 1. Whether 
differences in loading dose strategies between the EU-PACT and COAG trials contributed to 
differing results is not known. If loading doses are to be used, a genetically-informed approach to 
calculating the loading dose may be helpful. The majority of the experience with a genetically-
informed loading regimen is in those of European ancestry.  Determination of maintenance dose 
would be as described above.   
 
Non-African ancestry recommendation. In patients who self-identify as non-African ancestry, 
the recommendation, as summarized in Figure 2, is to:  1) calculate warfarin dosing using a 
published pharmacogenetic algorithm (16, 17), including genotype information for VKORC1-
1639G>A and CYP2C9*2 and *3. In individuals with genotypes associated with CYP2C9 poor 
metabolism (e.g., CYP2C9 *2/*3, *3/*3) or both increased sensitivity (VKORC1-1639 A/A) and 
CYP2C9 poor metabolism, an alternative oral anticoagulant might be considered (40). The bulk 
of the literature informing these recommendations is in European and Asian ancestry 
populations, but consistent data exist for other non-African populations.  These 
recommendations are graded as STRONG.  2) If a loading dose is to be utilized, the EU-PACT 
loading dose algorithm that incorporates genetic information could be used (33).  This 
recommendation is OPTIONAL. 3) While CYP2C9*5, *6, *8, or*11 variant alleles are 
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commonly referred to as African specific alleles, they can occur among individuals who do not 
identify as, or know of their, African ancestry.  If these variant alleles are detected, decrease 
calculated dose by 15-30% per variant allele or consider an alternative agent. Larger dose 
reductions might be needed in patients homozygous for variant alleles (i.e. 20-40%, e.g. 
CYP2C9*2/*5). This recommendation is graded as OPTIONAL.  4) If the CYP4F2*3 (i.e., 
c.1297A, p.433Met) allele is also detected, increase the dose by 5-10%.  This recommendation is 
also considered OPTIONAL.   5) The data do not suggest an association between rs12777823 
genotype and warfarin dose in non-African Americans, thus rs12777823 should not be 
considered in these individuals (even if available).     
 
African ancestry recommendation. In patients of African ancestry, CYP2C9*5, *6, *8, *11 are 
important for warfarin dosing. If these genotypes are not available, warfarin should be dosed 
clinically without consideration for genotype. If CYP2C9*5, *6, *8, and *11 are known, then the 
recommendation, as shown in Figure 2, is to: 1) calculate warfarin dose using a validated 
pharmacogenetic algorithm, including genotype information for VKORC1 c.-1639G>A and 
CYP2C9*2 and *3 (16, 17); 2) if the individual carriers a CYP2C9*5, *6, *8, or *11 variant 
allele(s), decrease calculated dose by 15-30%. Larger dose reductions might be needed in 
patients who carry two variant alleles (e.g., CYP2C9*5/*6) (i.e. 20-40% dose reduction). 3) In 
addition, rs12777823 is associated with warfarin dosing in African Americans (mainly 
originating from West Africa). Thus, in African Americans a dose reductions of 10-25% in those 
with rs12777823 A/G or A/A genotype is recommended.  These recommendations are 
considered MODERATE.    
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In individuals with genotypes that predict CYP2C9 poor metabolism or who have increased 
warfarin sensitivity (VKORC1 c.-1639 A/A) and CYP2C9 poor metabolism, an alternative oral 
anticoagulant should be considered (see Supplemental material for definitions of strength of 
recommendations).  As noted above, for non-African ancestry, if a loading dose is to be used, the 
EU-PACT algorithm (33) that incorporates genetic information could be used to calculate 
loading dose.  This recommendation is OPTIONAL.  The data do not support an impact on 
clinical phenotype for CYP4F2 on warfarin dosing in those of African ancestry and so no 
recommendation is made for use of CYP4F2 genotype data in blacks.  
 
Recommendations for Pediatric Patients. As detailed in Supplemental Table S7, there is strong 
evidence for the use of CYP2C9*2 and *3 and VKORC1-1639G>A genotype to guide warfarin 
dosing in children of European ancestry. The studies in Japanese pediatric individuals are 
conflicting as VKORC1 and CYP2C9 could not be adequately evaluated due to the low numbers 
of CYP2C9 variant carriers. For other ethnicities, there is no evidence documenting that 
VKORC1 and CYP2C9 are important. Furthermore, there are no data in children that included 
CYP2C9*5, *6, *8, or *11 genotyping. Based on the current evidence, in children of European 
ancestry and if CYP2C9*2 and *3 and VKORC1-1639 genotype are available, calculate warfarin 
dosing based on a validated published pediatric pharmacogenetic algorithm (Figure 3) (41, 42).  
A dosing tool that can be used in children of European ancestry is available at 
http://www.warfarindoserevision.com (43). 
 
Other considerations 
Given the effects of CYP2C9 on warfarin clearance, and given that the CYP2C9 variant alleles 
are associated with reduced warfarin clearance, CYP2C9 genotype may influence time to onset 
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and offset of anticoagulation, as measured by INR (44). The Supplemental Material 
summarizes other considerations in the dosing of warfarin, including clinical factors and 
interacting drugs, some of which are included in the pharmacogenetic dosing algorithms (see 
Text Box).  Other genes of potential importance are detailed in the Supplemental Material and 
Supplemental table S6, including CALU and GGCX.  Most clinical genotyping platforms do not 
include these genes, nor do the dosing tables or published algorithms.  The Supplemental 
Material also discusses incorporation of genetic information into the initial dose, and 
alternatives to warfarin. 
 
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT  
Incorporation of genetic information has the potential to shorten the time to stable INR, increase 
the time within the therapeutic INR range, and reduce under-dosing or over-dosing during the 
initial treatment period (33).  If these benefits are achieved, they could result in a reduced risk of 
bleeding and thromboembolic events (12, 45).  There are also potential risks.  For example, using 
genetic information to guide dosing may lead to false security and inadequate INR monitoring.  
In particular, there are risks of using pharmacogenetic dosing in those of African ancestry if only 
CYP2C9 *2 and *3 alleles are included.  Genetic-guided dosing may increase the risk for over-
dosing or under-dosing, especially in individuals who carry rare or untested variants and are 
assigned as “wild-type” by default (17, 32).  The cost-benefit of genetic-guided therapy depends 
on the cost of genotyping and the reduction in adverse events (46), and most insurance plans do 
not currently pay for warfarin pharmacogenetic testing.  Although there is substantial evidence 
associating CYP2C9 and VKORC1 variants with warfarin dosing, randomized clinical trials have 
demonstrated inconsistent results in terms of clinical outcomes (see Linking genetic variability to 
variability in drug-related phenotypes). Although genotyping is reliable when performed in 
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qualified laboratories, an additional risk is an error in genotyping or reporting of genotype.   
Genotypes are life-long test results, so such error could have long-term adverse health 
implications. 
 
CAVEATS:  APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC 
TESTS  
Many pharmacogenetic dosing algorithms are developed for a target INR of 2-3 (17) and so their 
utility for estimating therapeutic warfarin doses with other target INR ranges is uncertain; 
however, some algorithms accommodate the target INR explicitly (16, 43).  Pharmacogenetic-
guided warfarin dosing does not alter the requirements for regular INR monitoring.  There are 
patients for whom genetic testing is likely to be of little or no benefit, including those who 
already have had long-term treatment with stable warfarin doses and those who are unable to 
achieve stable dosing due to variable adherence.  The greatest potential benefit is early in the 
course of therapy (before therapy initiation or in the early days of therapy) (36). It is likely that 
patients on therapy for many weeks to months, with careful INR monitoring, will derive little 
benefit from subsequent warfarin pharmacogenetics testing (47).  
 
DISCLAIMER 
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert 
consensus based on clinical evidence and peer-reviewed literature available at the time they are 
written and are intended only to assist clinicians in decision-making and to identify questions for 
further research. New evidence may have emerged since the time a guideline was submitted for 
publication. Guidelines are limited in scope and are not applicable to interventions or diseases 
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not specifically identified. Guidelines do not account for all individual variations among patients 
and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. 
It remains the responsibility of the health care provider to determine the best course of treatment 
for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding 
its application to be made solely by the clinician and the patient. CPIC assumes no responsibility 
for any injury to persons or damage to persons or property arising out of or related to any use of 
CPIC's guidelines, or for any errors or omissions. 
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Text box. Patient characteristics utilized in the Gage (16), or IWPC (17) algorithms or both 
 Age 
 Sex 
 Race 
 Weight 
 Height 
 Smoking status 
 Warfarin indication 
 Target INR 
 Interacting drugs 
o Inhibitors: Amiodarone, statins, sulfamethoxazole, azole antifungals 
o Inducers: Rifampin, phenytoin, carbamazepine 
 Genetic variables 
o CYP2C9 genotype 
o VKORC1 genotype 
o Gage algorithm can also incorporate CYP4F2 and GGCX genotypes 
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Figure legends 
Figure 1. Schematic representation of warfarin metabolism and its mechanism of action. 
Warfarin is administered via a racemic mixture of the R- and S- stereoisomers.  S-warfarin is 3-5 
times more potent than R-warfarin and is metabolized predominantly to 7- and 6- hydroxyl 
metabolites via CYP2C9. Warfarin exerts its anticoagulant effect through inhibition of its 
molecular target VKORC1, which in turn limits availability of reduced vitamin K, leading to 
decreased formation of functionally active clotting factors. These clotting factors are 
glycoproteins that are post-translationally carboxylated by gamma-glutamyl carboxylase 
(GGCX) to Gla-containing proteins. The endoplasmic reticulum chaperone protein calumenin 
(CALU) can bind to and inhibit GGCX activity.  The metabolism of reduced vitamin K to 
hydroxyvitamin K1 is catalyzed by CYP4F2 which removes vitamin K from the vitamin K cycle 
(adapted from warfarin pharmacokinetics (PK) and pharmacodynamics (PD) pathways at 
PharmGKB, 
http://www.pharmgkb.org/do/serve?objId=PA451906&objCls=Drug#tabview=tab4). 
 
Figure 2.  
 
Figure 3.   
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FIGURE 2.  DOSING RECOMMENDATIONS FOR WARFARIN DOSING BASED ON GENOTYPE FOR ADULT 
PATIENTS 
a
“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose 
approach 
bData strongest for European and East Asian ancestry populations and consistent in other populations. 
c
45-50% of individuals with self-reported African ancestry carry CYP2C9*5,*6,*8,*11, or rs12777823. IF CYP2C9*5, *6, *8, and *11 
WERE NOT TESTED, DOSE WARFARIN CLINICALLY.  Note: these data derive primarily from African Americans, who are 
largely from West Africa.  It is unknown if the same associations are present for those from other parts of Africa.   
dMost algorithms are developed for the target INR 2-3.  
eConsider an alternative agent in individuals with genotypes associated with CYP2C9 poor metabolism (e.g., CYP2C9*3/*3, *2/*3, 
*3/*3) or both increased sensitivity (VKORC1 A/G or A/A) and CYP2C9 poor metabolism. 
f
See the EU-PACT trial for pharmacogenetics-based warfarin initiation (loading) dose algorithm (33) with the caveat that the loading 
dose PG algorithm has not been specifically tested or validated in populations of African ancestry. 
g 
Larger dose reduction might be needed in variant homozygotes (i.e. 20-40%).  
h
African American refers to individuals mainly originating from West Africa.   
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FIGURE 3.  DOSING RECOMMENDATIONS FOR WARFARIN DOSING BASED ON GENOTYPE FOR PEDIATRIC 
PATIENTS  
a
Data strongest for European ancestry populations and consistent in most Japanese studies.  
b
“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose 
approach 
cValidated published pediatric pharmacogenetic algorithms include Hamberg et al.(43) and Biss et al.(42)  
dNo studies in children included CYP2C9*5, *6, *8, or *11 genotyping. 
 
28 
 
REFERENCES: 
(1) Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation 
Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther  89, 464-
7 (2011). 
(2) Pengo, V., Pegoraro, C., Cucchini, U. & Iliceto, S. Worldwide management of oral 
anticoagulant therapy: the ISAM study. Journal of thrombosis and thrombolysis  21, 73-7 
(2006). 
(3) Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. Pharmacology 
and management of the vitamin K antagonists: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest  133, 160S-98S (2008). 
(4) Kearon, C. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and 
Expert Panel Report. Chest  149, 315-52 (2016). 
(5) Shehab, N., Sperling, L.S., Kegler, S.R. & Budnitz, D.S. National estimates of 
emergency department visits for hemorrhage-related adverse events from clopidogrel 
plus aspirin and from warfarin. Arch Intern Med  170, 1926-33 (2010). 
(6) Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation 
factor deficiency type 2. Nature  427, 537-41 (2004). 
(7) Perera, M.A. et al. Genetic variants associated with warfarin dose in African-American 
individuals: a genome-wide association study. Lancet  382, 790-6 (2013). 
(8) Lee, C.R., Goldstein, J.A. & Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a 
comprehensive review of the in-vitro and human data. Pharmacogenetics  12, 251-63 
(2002). 
(9) Gene Refernece Materials for CYP2C9. 
<https://www.pharmgkb.org/page/cyp2c9RefMaterials> (2016). Accessed November 4, 
2016. 
(10) Limdi, N.A. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is 
predictive of dose across 3 racial groups. Blood  115, 3827-34 (2010). 
(11) Aithal, G.P., Day, C.P., Kesteven, P.J. & Daly, A.K. Association of polymorphisms in 
the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding 
complications. Lancet  353, 717-9 (1999). 
(12) Mega, J.L. et al. Genetics and the clinical response to warfarin and edoxaban: findings 
from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet  385, 2280-7 
(2015). 
(13) Wajih, N., Hutson, S.M., Owen, J. & Wallin, R. Increased production of functional 
recombinant human clotting factor IX by baby hamster kidney cells engineered to 
overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K 
cycle. The Journal of biological chemistry  280, 31603-7 (2005). 
(14) Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with 
warfarin dose. Pharmacogenomics J  5, 262-70 (2005). 
(15) Yuan, H.Y. et al. A novel functional VKORC1 promoter polymorphism is associated 
with inter-individual and inter-ethnic differences in warfarin sensitivity. Human 
molecular genetics  14, 1745-51 (2005). 
(16) Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic 
dose of warfarin. Clin Pharmacol Ther  84, 326-31 (2008). 
29 
 
(17) Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. 
The New England journal of medicine  360, 753-64 (2009). 
(18) Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and 
warfarin dose. N Engl J Med  352, 2285-93 (2005). 
(19) Gene Reference Materials for VKORC1. 
<https://www.pharmgkb.org/page/vkorc1RefMaterials>. Accessed November 4, 2016. 
(20) Scott, S.A., Edelmann, L., Kornreich, R. & Desnick, R.J. Warfarin pharmacogenetics: 
CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies 
in the Ashkenazi and Sephardi Jewish populations. American journal of human genetics  
82, 495-500 (2008). 
(21) McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. & Rettie, A.E. CYP4F2 is a 
vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M 
variant. Molecular pharmacology  75, 1337-46 (2009). 
(22) Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood  111, 
4106-12 (2008). 
(23) Stec, D.E., Roman, R.J., Flasch, A. & Rieder, M.J. Functional polymorphism in human 
CYP4F2 decreases 20-HETE production. Physiol Genomics  30, 74-81 (2007). 
(24) Gene Refernece Materials for CYP4F2. 
<https://www.pharmgkb.org/page/cyp4f2RefMaterials>. Accessed November 4, 2016. 
(25) Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) significantly contributes to 
warfarin dosing variability in the Italian population. Pharmacogenomics  10, 261-6 
(2009). 
(26) Danese, E. et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose 
requirement: systematic review and meta-analysis. Clin Pharmacol Ther  92, 746-56 
(2012). 
(27) Zhang, J.E. et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical 
outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics  19, 781-9 
(2009). 
(28) Alzubiedi, S. & Saleh, M.I. Pharmacogenetic-guided Warfarin Dosing Algorithm in 
African-Americans. J Cardiovasc Pharmacol  67, 86-92 (2016). 
(29) Oldenburg, J. et al. Congenital deficiency of vitamin K dependent coagulation factors in 
two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. 
Thrombosis and haemostasis  84, 937-41 (2000). 
(30) Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic 
forecasting. Blood,  (2008). 
(31) Liang, R., Wang, C., Zhao, H., Huang, J., Hu, D. & Sun, Y. Influence of CYP4F2 
genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb 
Res  130, 38-44 (2012). 
(32) Kimmel, S.E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N 
Engl J Med  369, 2283-93 (2013). 
(33) Pirmohamed, M. et al. A randomized trial of genotype-guided dosing of warfarin. N Engl 
J Med  369, 2294-303 (2013). 
(34) Drozda, K. et al. Poor warfarin dose prediction with pharmacogenetic algorithms that 
exclude genotypes important for African Americans. Pharmacogenet Genomics  25, 73-
81 (2015). 
30 
 
(35) Do, E.J. et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein 
thrombosis (DVT): rationale and study design. Pharmacogenomics J  12, 417-24 (2012). 
(36) Lenzini, P. et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. 
Clin Pharmacol Ther  87, 572-8 (2010). 
(37) Avery, P.J. et al. A proposal for an individualized pharmacogenetics-based warfarin 
initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol 
Ther  90, 701-6 (2011). 
(38) Finkelman, B.S., Gage, B.F., Johnson, J.A., Brensinger, C.M. & Kimmel, S.E. Genetic 
warfarin dosing: tables versus algorithms. J Am Coll Cardiol  57, 612-8 (2011). 
(39) Arwood, M.J. et al. Anticoagulation endpoints with clinical implementation of warfarin 
pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic 
dosing approach. Clin Pharmacol Ther,  (2016). 
(40)  (!!! INVALID CITATION !!! (12)). 
(41) Hamberg, A.K. et al. Warfarin dose prediction in children using pharmacometric 
bridging--comparison with published pharmacogenetic dosing algorithms. Eur J Clin 
Pharmacol  69, 1275-83 (2013). 
(42) Biss, T.T. et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a 
large proportion of the variability in warfarin dose requirement among children. Blood  
119, 868-73 (2012). 
(43) Hamberg, A.K., Wadelius, M., Friberg, L.E., Biss, T.T., Kamali, F. & Jonsson, E.N. 
Characterizing variability in warfarin dose requirements in children using modelling and 
simulation. Br J Clin Pharmacol  78, 158-69 (2014). 
(44) Hamberg, A.K. et al. A pharmacometric model describing the relationship between 
warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and 
age. Clin Pharmacol Ther  87, 727-34 (2010). 
(45) Oden, A. & Fahlen, M. Oral anticoagulation and risk of death: a medical record linkage 
study. BMJ  325, 1073-5 (2002). 
(46) Eckman, M.H., Rosand, J., Greenberg, S.M. & Gage, B.F. Cost-effectiveness of using 
pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial 
fibrillation. Ann Intern Med  150, 73-83 (2009). 
(47) Ferder, N.S. et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose 
during the initial weeks of therapy. J Thromb Haemost  8, 95-100 (2010). 
 
